SFJ Pharmaceuticals, Inc.
Marc Cobo has a strong background in finance and accounting, with extensive experience in various leadership roles. Marc currently serves as the Executive Vice President and Chief Accounting Officer at SFJ Pharmaceuticals, Inc. Since joining in March 2021. Prior to this, they worked at Tricida, Inc. as the Senior Vice President of Finance and Chief Accounting Officer from June 2020 to December 2020.
From 2014 to 2019, Marc held several positions at Sangamo Therapeutics, Inc., including Vice President of Finance, Controller, and Assistant Controller. In these roles, they were responsible for managing a team and overseeing various accounting functions such as billing, payroll, expense reimbursement, and stock administration. Marc also played a key role in the integration of financials during a business combination of a French company.
Before Sangamo Therapeutics, Marc worked at Responsys as a Senior Manager of Accounting from June 2012 to March 2014. Marc was responsible for financial reporting, technical accounting, stock administration, and participated in mergers and acquisitions. Prior to that, they worked at Oracle from 2006 to 2012, where they held roles as a Manager in M&A and Technical Accounting, Manager in Corporate Reporting, and Senior Analyst in Corporate Reporting. Marc'sresponsibilities at Oracle included conducting due diligence on acquisition targets, preparing SEC filings, and coordinating with internal organizations for quarterly reporting.
Marc started their career at Ernst & Young LLP as a Senior Auditor from September 2002 to November 2006. Marc managed engagement teams and conducted financial statement audits for public and private companies.
Overall, Marc Cobo brings a wealth of experience in finance and accounting, with a track record of leadership and expertise in various aspects of the field.
Marc Cobo attended Santa Clara University Leavey School of Business where they pursued a degree in Accounting. Marc'sfield of study focused on Accounting and Finance. Additionally, they obtained the certification as a Certified Public Accountant from the State of California. The specific start and end years of their education and the month and year they obtained the certification are not provided.
SFJ Pharmaceuticals, Inc.
The SFJ Pharmaceuticals Group ® mission is to accelerate the availability of new and innovative drugs into the world’s major markets, by providing not only additional funding, but also strategic development expertise to enable our Pharma and Biotech partners to be as hands off or as hands on as they wish. Currently there is significant downwardpressure on drug development resources. In the case of large Pharma the so called “patent cliff” has hit hard leaving no company unaffected. This leads to dramatic R+D budget cuts. For Biotech there is a chronic lack of external funding available. The SFJ Pharmaceuticals Group ® mission is to enable these companies to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves. SFJ will take 100% of the clinical and regulatory risk.